Effect of Ischemic Postconditioning on Myocardial Function and Infarct Size Following Reperfusion Injury in Diabetic Rats Pretreated With Vildagliptin
- PMID: 28901167
- DOI: 10.1177/1074248417729881
Effect of Ischemic Postconditioning on Myocardial Function and Infarct Size Following Reperfusion Injury in Diabetic Rats Pretreated With Vildagliptin
Abstract
Background: Cardioprotective actions of ischemic postconditioning (IPostC) against ischemia/reperfusion (I/R) injury are abolished in diabetic hearts. This study has investigated the combined effects of IPostC and vildagliptin (Vilda) on myocardial function and infarct size (IS) against I/R injury in diabetic myocardium.
Methods: Diabetes was induced by a high-fat diet/low dose of streptozotocin (35 mg/kg; intraperitoneally) in Wistar rats (200-250 g) and lasted for 12 weeks. Vilda (6 mg/kg/d) was orally administered for 5 weeks in diabetic groups after seventh week of diabetes. At the end of the 12-week period, the hearts of rats were removed and subjected to 35-minute regional ischemia (through left anterior descending ligation) followed by 60-minute reperfusion, on Langendorff apparatus. Ischemic postconditioning was induced by 6 repetitive cycles of 10-second ischemia and 10-second reperfusion, immediately at the onset of the reperfusion. Myocardial hemodynamic was measured throughout the experiment. The IS was assessed by triphenyltetrazolium chloride staining method. The myocardial contents of troponin-I (cTnI), interleukin-6 (IL-6), and 8-isoprostane were measured in the homogenate from ischemic zone of left ventricles by enzyme-linked immunosorbent assay kit.
Results: Pretreatment of the diabetic rats with Vilda significantly recovered the diabetes-induced reduction in left ventricular developed pressures and contractility at the baseline ( P < .05 to P < .01). After I/R injury, IPostC could not significantly improve the myocardial function, cTnI content, and IS of the diabetic hearts. However, in Vilda-treated hearts, concomitant application of IPostC significantly recovered the heart functions, returned cTnI content as well as myocardial IL-6 and 8-isoprostane levels back to the control values ( P < .01 to P < .001), and reduced IS more effectively (by 45%) in comparison to the diabetic group ( P < .001).
Conclusion: Besides its glycemic and lipid profile controlling effects, Vilda has a protective effect on heart function and tends to restore cardioprotective effects of IPostC on diabetic hearts.
Keywords: cardioprotection; diabetes; infarct size; ischemic postconditioning; reperfusion injury.
Similar articles
-
Pretreatment with vildagliptin boosts ischemic-postconditioning effects on cardioprotection and expression profile of genes regulating autophagy and mitochondrial fission/fusion in diabetic heart with reperfusion injury.Naunyn Schmiedebergs Arch Pharmacol. 2019 Nov;392(11):1371-1382. doi: 10.1007/s00210-019-01660-z. Epub 2019 Jun 22. Naunyn Schmiedebergs Arch Pharmacol. 2019. PMID: 31230090
-
The additive effects of ischemic postconditioning and cyclosporine-A on nitric oxide activity and functions of diabetic myocardium injured by ischemia/reperfusion.J Cardiovasc Pharmacol Ther. 2012 Jun;17(2):181-9. doi: 10.1177/1074248411416118. Epub 2011 Aug 9. J Cardiovasc Pharmacol Ther. 2012. PMID: 21828282
-
Chronic type-I diabetes could not impede the anti-inflammatory and anti-apoptotic effects of combined postconditioning with ischemia and cyclosporine A in myocardial reperfusion injury.J Physiol Biochem. 2017 Feb;73(1):111-120. doi: 10.1007/s13105-016-0530-4. Epub 2016 Oct 22. J Physiol Biochem. 2017. PMID: 27771871
-
Signaling mediators modulated by cardioprotective interventions in healthy and diabetic myocardium with ischaemia-reperfusion injury.Eur J Prev Cardiol. 2018 Sep;25(14):1463-1481. doi: 10.1177/2047487318756420. Epub 2018 Feb 14. Eur J Prev Cardiol. 2018. PMID: 29442529 Review.
-
Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.Pharmacol Rev. 2007 Dec;59(4):418-58. doi: 10.1124/pr.107.06002. Epub 2007 Nov 29. Pharmacol Rev. 2007. PMID: 18048761 Review.
Cited by
-
Combination of Vildagliptin and Ischemic Postconditioning in Diabetic Hearts as a Working Strategy to Reduce Myocardial Reperfusion Injury by Restoring Mitochondrial Function and Autophagic Activity.Adv Pharm Bull. 2018 Jun;8(2):319-329. doi: 10.15171/apb.2018.037. Epub 2018 Jun 19. Adv Pharm Bull. 2018. PMID: 30023334 Free PMC article.
-
Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms.Naunyn Schmiedebergs Arch Pharmacol. 2022 Nov;395(11):1357-1372. doi: 10.1007/s00210-022-02279-3. Epub 2022 Aug 10. Naunyn Schmiedebergs Arch Pharmacol. 2022. PMID: 35945358 Free PMC article. Review.
-
H3K14 hyperacetylation‑mediated c‑Myc binding to the miR‑30a‑5p gene promoter under hypoxia postconditioning protects senescent cardiomyocytes from hypoxia/reoxygenation injury.Mol Med Rep. 2021 Jun;23(6):468. doi: 10.3892/mmr.2021.12107. Epub 2021 Apr 21. Mol Med Rep. 2021. PMID: 33880587 Free PMC article.
-
Human amniotic membrane mesenchymal stem cells-conditioned medium attenuates myocardial ischemia-reperfusion injury in rats by targeting oxidative stress.Iran J Basic Med Sci. 2020 Nov;23(11):1453-1461. doi: 10.22038/ijbms.2020.47572.10952. Iran J Basic Med Sci. 2020. PMID: 33235703 Free PMC article.
-
Preclinical multi-target strategies for myocardial ischemia-reperfusion injury.Front Cardiovasc Med. 2022 Aug 22;9:967115. doi: 10.3389/fcvm.2022.967115. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36072870 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials